Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS7 | Q9UKP4 | 19/20 | 0.76 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP3 | P08254 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.36 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23354223 | 0.89 | ADAMTS7 (0.80) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL29979170 | 0.89 | ADAMTS7 (0.80) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL23371320 | 0.87 | ADAMTS7 (0.77) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL24927956 | 0.87 | ADAMTS7 (0.82) | ADAMTS7 | |
| SCHEMBL29978869 | 0.87 | ADAMTS7 (0.82) | ADAMTS7 | |
| SCHEMBL29979132 | 0.86 | ADAMTS7 (1.00) | ADAMTS7ADAMTS4ADAMTS5 | |
| SCHEMBL23353983 | 0.86 | ADAMTS7 (1.00) | ADAMTS7ADAMTS4ADAMTS5 | |
| SCHEMBL29979438 | 0.83 | ADAMTS7 (0.62) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL24928067 | 0.80 | ADAMTS7 (0.62) | ADAMTS7ADAMTS4MMP2MMP3MMP13 | |
| SCHEMBL29979270 | 0.80 | ADAMTS7 (0.62) | ADAMTS7ADAMTS4MMP2MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| WO-2021094436-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-05-20 | — | — | WO | disclosed |
| EP-3822268-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | Bayer Aktiengesellschaft (DE) | 2021-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230027346-A1 | SUBSTITUTED HYDANTOINAMIDES AS ADAMTS7 ANTAGONISTS | ADAMTS7, MMP7, ADAM17 | ADAMTS7 1/4885ADAMTS4 6/4885MMP2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.